Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.48 |
| ▸ | CNR2 | P34972 | 10/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775561 | 0.84 | MAPT (0.43) | CACNA1G | |
| SCHEMBL4773088 | 0.80 | SIGMAR1 (0.36) | CNR1CNR2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL7392463 | 0.77 | CACNA1B (0.51) | CNR1CACNA1GCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4771297 | 0.75 | NPSR1 (0.46) | — | |
| SCHEMBL4778352 | 0.73 | ALDH1A1 (0.40) | CNR1OPRM1OPRK1 | |
| SCHEMBL4774991 | 0.73 | LMNA (0.39) | — | |
| SCHEMBL4779187 | 0.72 | MAPT (0.42) | — | |
| SCHEMBL4778523 | 0.72 | SCD (0.40) | CNR1CNR2CACNA1GCACNA2D1CACNA1B | |
| SCHEMBL4772508 | 0.71 | CYP3A4 (0.36) | CNR1CNR2CACNA1GCACNA2D1CACNA1B | |
| SCHEMBL6167915 | 0.70 | TP53 (0.40) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |